anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Macrophage activation syndrome is a rare disorder leading to unregulated immune activity manifesting with nonspecific constitutional symptoms, laboratory abnormalities, and multiorgan involvement. We report the case of a patient who presented with acute hepatitis secondary to macrophage activation syndrome diagnosed by liver biopsy and successfully treated with intravenous immune globulin, anakinra, and rituximab.
CASE PRESENTATION: A 42-year-old Laotian woman with adult-onset immunodeficiency with anti-interferon gamma antibodies presented with a fever, headache, generalized myalgia, dark urine, and reduced appetite in the setting of family members at home with similar symptoms. Her laboratory workup was notable for evidence of acute hepatitis without acute liver failure. After an unrevealing comprehensive infectious and noninvasive rheumatologic workup was completed, a liver biopsy was performed ultimately revealing the diagnosis of macrophage activation syndrome. She was successfully treated with intravenous immune globulin, anakinra, and rituximab.
CONCLUSION: This case highlights the importance of maintaining macrophage activation syndrome on the differential of a patient with acute hepatitis of unknown etiology in the correct clinical context and the value of a liver biopsy in making a diagnosis when noninvasive testing is unrevealing.
Cyclobenzaprine hydrochloride may have life-threatening interactions with MAO inhibitors. (See CONTRAINDICATIONS.) Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. If concomitant treatment with cyclobenzaprine hydrochloride and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dose increases (see WARNINGS). 

Cyclobenzaprine hydrochloride may enhance the effects of alcohol, barbiturates, and other CNS depressants.

Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.

Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.
Background and Objectives: This study aimed to compare the effects and safety of boldine combined with Phyllanthus niruri and Ononis spinosa plus tamsulosin vs. tamsulosin alone in medical expulsive therapy (MET) for distal ureteral calculi. Materials and Methods: This retrospective cohort study was conducted on 159 renal colic patients with distal ureteric stones (≤10 mm). Patients aged between 18 and 70 years or older with distal ureteral (below the sacroiliac joint) stones ≤10 mm (defined by the largest diameter in three planes) confirmed by urinary ultrasonography and/or native computed tomography (CT). Patients were divided into two groups: A and B. Patients in Group A received tamsulosin 0.4 mg plus boldine combined with Phyllanthus niruri and Ononis spinosa, while those in Group B received tamsulosin 0.4 mg. The rate of stone expulsion, duration of stone expulsion, the dose and the duration of nonsteroidal anti-inflammatory drugs (NSAIDs), analgesic use, and adverse effects of drugs were recorded. Results: No differences were reported in demographic profiles between the two groups. The stone expulsion rate in Group A (84.8%) was higher in comparison to Group B (52.5%); the mean time of stone expulsion was 16.33 ± 4.75 days in Group A and 19.33 ± 6.42 days in Group B. The mean requirement time of analgesia was significantly less in Group A, 2.42 ± 2.56, than in Group B, 6.25 ± 3.05. Drug-related adverse effects (headache, dizziness, nausea, vomiting, postural hypotension, backache, and running nose) were comparable between the two groups. Conclusions: Tamsulosin plus boldine combined with Phyllanthus niruri and Ononis spinosa as medical expulsion therapy is more effective for distal ureteric stones with less need for analgesics and a shorter stone expulsion time than tamsulosin alone.
Participants may receive 1 or 2 doses of imlifidase, depending on rAAVrh74 antibody titer results. Then, based on their rAAVrh74 antibody titer, eligible participants may receive 1 dose of delandistrogene moxeparvovec infusion.
Experimental group will take medicine for 10 weeks from 2 weeks before surgery to 8 weeks after surgery. The group takes one pill of duloxetine 30 mg, one pill of pregabalin 150mg after breakfast and one pill of pregabalin 150 mg after dinner.
Subjects will be asked to take the dietary supplement daily for 8 weeks. Blood samples will be taken at screen, baseline and week 8. An oral glucose tolerance test will be taken at baseline and week 8. Additionally subjects will be asked to collect their stool samples at Baseline, week 4, and 8. Subjects will also undergo a test to determine their body composition at baseline and week 8. Subjects will be asked to keep a diary of their bowel habits and any symptoms that might be related to the supplement. Subjects will be asked to recall the foods that they have eaten in the past 24 hours and to avoid any foods that contain XOS and probiotic bacteria during the study.
Methods, non-transitory computer readable media, and surgical computing devices are illustrated that improve surgical planning using machine learning. With this technology, a machine learning model is trained based on historical case log data sets associated with patients that have undergone a surgical procedure. The machine learning model is applied to current patient data for a current patient to generate a predictor equation. The current patient data comprises anatomy data for an anatomy of the current patient. The predictor equation is optimized to generate a size, position, and orientation of an implant, and resections required to achieve the position and orientation of the implant with respect to the anatomy of the current patient, as part of a surgical plan for the current patient. The machine learning model is updated based on the current patient data and current outcome
The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put "hands on" caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge; (iii) using telephone support, counselling caregivers on 3rd, 6th, 8th and 10th weeks post discharge. It aims at facilitating the caregivers 'adjustment to stroke demands, increasing knowledge and practical skills to support their decision-making.
The present invention relates to a freeze-dried matrix of aloe vera and collagen that forms a cool gel when activated by addition of sterilized water. The cool gel is suitable as a first aid treatment for minor burns. Further embodiments of the invention incorporate the above-described cool gel into a band-aid, bandage or wound dressing, including securing the cool gel beneath an adhesive, preferably a silicone-based adhesive, associated with the band-aid, bandage or wound dressing. 4. Drawings Burneez drawings Fig 1. Exploded view of treatment device: 1.1 collagen/Aloe vera matrix 1.2 woven sterile crosshatch 13 1.3 gauze/cotton pad 1.4 underside of outer film, with non-latex adhesive 30-5Omicrons Fig 2 unexploded image of treatment device Fig 3 activation method 3.1 sterile water atomizer-style dispenser 3.2 spray 3.3 treatment device/wound cover Fig 4 image of wounded hand, upon which fig 3.3 to be placed after activation of freeze-dried matrix
MPZL2-related hearing loss is a rare form of autosomal recessive hearing loss characterized by progressive, mild sloping to severe sensorineural hearing loss. Thirty-five previously reported patients had biallelic truncating variants in MPZL2, with the exception of one patient with a missense variant of uncertain significance and a truncating variant. Here, we describe the clinical characteristics and genotypes of five patients from four families with confirmed MPZL2-related hearing loss. A rare missense likely pathogenic variant [NM_005797.4(MPZL2):c.280C>T,p.(Arg94Trp)] located in exon 3 was confirmed to be in trans with a recurrent pathogenic truncating variant that segregated with hearing loss in three of the patients from two unrelated families. This is the first recurrent likely pathogenic missense variant identified in MPZL2. Apparently milder or later-onset hearing loss associated with rare missense variants in MPZL2 indicates that some missense variants in this gene may cause a milder phenotype than that resulting from homozygous or compound heterozygous truncating variants. This study, along with the identification of truncating loss of function and missense MPZL2 variants in several diverse populations, suggests that MPZL2-related hearing loss may be more common than previously appreciated and demonstrates the need for MPZL2 inclusion in hearing loss testing panels.
The present application relates to a method for managing healthcare services by using a therapy management system. The method comprises the following steps: the method includes wirelessly receiving quality care information from a patient mobile communication device, reporting the quality care information to a quality tracking system, and receiving incentive rewards in response to reporting the quality care information to the quality tracking system. The quality of care information may relate to one or more quality of care indicators for motivating a provider or consumer of the healthcare service. The patient may be alerted to a quality of care indicator of a particular medical condition. Personalized and specific notifications generated by applications residing in the patient's mobile device or running in the cloud may be electronically transmitted to the patient, including prompting the patient to take specific actions to best manage the medical condition or prescribed treatment. The healthcare provider may be notified of treatment or care quality advice actions to be taken.
Data from 16322 (10336 females) participants of the Swiss health survey (SHS) 2007 will serve as control. The SHS was performed in 2007, a representative sample of 30000 Swiss citizens were asked to participate, 66% answered per telephone to detailed health question.
1. Lyophilized composition comprising trehalose and lipid liposomes in hich a biologically-active principle has been incorporated, characterized in that the biologically-active principle is highly insoluble in water, the trehalose/lipid weight ratio is <= 1.5, and all of the trehalose was added to the outside of the liposomes already formed before lyophilization. 2. Lyophilized composition according to Claim 1, characterized in that the biologically-active principle which is highly insoluble in water is chosen from the group comprising lonidamine, melatonin cyclosporin A and bindarit. 3. Lyophilized composition according to Claim 1 or 2, characterized in that the lipids are chosen from the group comprising phosphoglycerides, glycerides, diglycerides, triglycerides, phospholipids, galactosyl and glucosyl lipids, cholesterol and its derivatives, sphingolipids and their mixtures. 4. Lyophilized composition according to Claim 3, characterized in that the lipids are phospholipids. 5. Lyophilized composition according to any one of Claims 1 to 4, characterized in that the trehalose/lipid weight ratio is between 1:2 and 1:1. 6. Lyophilized composition according to any one of Claims 1 to 5, characterized in that the average size of the liposomes is between 50 and 250 nm. 7. Lyophilized composition according to Claim 6, characterized in that the average size of the liposomes is between 50 and 100 nm. 8. Process for lyophilizing a composition comprising trehalose and lipid liposomes, in which there has been incorporated a biologically-active principle characterized in that: a) from 0.2 to 1.5 parts in weight of trehalose are added for each part in weight of lipids of an aqueous liposome composition in which the average size of the liposomes is between 50 and 250 nm, said liposomes comprising a biologically-active principle which is highly insoluble in water; b) said composition is chilled by means of the chilling plate of the lyophilizer to a temperature between -5 degree  and -70 degree C, at a chilling rate of between 0.5 and 2 degree C/min.;c) once the predetermined freezing temperature has been reached, said composition is kept at said temperature for between 2 and 5 hours; d) a vacuum of between 5 x 10.1 and 8 x 102 millibar is applied, leaving the temperature of the chilling plate at the chilling temperature defined in point b) for a period of between 2 and 5 hours; e) the temperature of the chilling plate is brought to -15 C, and kept there until the water is completely removed. 9. Lyophilization process according to Claim 8, characterized in that, in Phase b), the freezing temperature is between -20 degree  and -30 degree C. 10. Lyophilization process according to Claim 8 or 9, characterized in that, in Phase b), the chilling rate is 0.77 degree C/min. 11. Lyophilization process according to any one of Claims 8 to 10, characterized in that, in Phase c), the time is 3 hours. 12. Lyophilization process according to any one of Claims 8 to 11, characterized in that, in Phase d), the vacuum is 6 x 10<-2> millibar.
A delivery vehicle for a silver ion source such as silver nitrate and the like, suitable for use in the treatment of menorrhagia, comprises a plurality of physiologically inert beads bearing a tissue cauterizing amount of a silver ion source. Preferably the beads are made of a physiologically inert polymer, ceramic or stainless steel. The silver ion source preferably is silver nitrate and can be substantially pure silver nitrate, or can comprise silver nitrate in combination with a physiologically tolerable binder or a diluent. Suitable binders include physiologically tolerable synthetic polymeric binders, polysaccharide binders, and the like. Diluents can include other salt materials such as potassium nitrate. The beads are useful in treating menorrhagia of a mammalian uterus. The beads can be delivered to the uterus via a catheter, and are distributed throughout the uterine cavity by uterine massage or like expedient. Silver ions are delivered to the endometrium and cause necrosis of the endometrial tissue. The silver ions remaining within the uterine cavity can then be neutralized with a sodium chloride solution delivered to the uterus e.g., by catheter, and the beads recovered from the uterus.
The goal of this study is to analyze the effect of frailty status on postoperative outcomes. These include postoperative complications (only ICD-10 coded diagnoses), length of hospitalization (ward/ICU), disposition, and survival. The project will also attempt to find synergism between a positive frailty status and common medical conditions (e.g. diabetes, congestive heart failure, coronary artery disease, dementia, and kidney disease), as well as anesthesiological and surgical processes (e.g. duration and type of anesthesia, surgical risk, and surgical discipline). Different assessment tools will be analyzed regarding their predictive power and clinical practicability. This should help improve preoperative risk assessment and allow for the multidimensional (physical, cognitive, social) identification of relevant frailty characteristics in the perioperative setting. All outcome parameters, including admission and discharge periods, will be collected using coded information from our hospital database. There will be no follow-up measurements after hospital discharge.
Rheumatoid arthritis is a common systemic inflammatory autoimmune disease characterized by damage to joints, inflammation and pain. It is driven by an increase of inflammatory cytokines and lipids mediators such as prostaglandins. Epoxides of polyunsaturated fatty acids (PUFAs) are lipid chemical mediators in a group of regulatory compounds termed eicosanoids. These epoxy fatty acids (EpFA) have resolutive functions but are rapidly metabolized by the soluble epoxide hydrolase enzyme (sEH) into the corresponding diols. The pharmacological inhibition of sEH stabilizes EpFA from hydrolysis, improving their half-lives and biological effects. These anti-inflammatory EpFA, are analgesic in neuropathic and inflammatory pain conditions. Nonetheless, inhibition of sEH on arthritis and the resulting effects on eicosanoids profiles are little explored despite the physiological importance. In this study, we investigated the effect of sEH inhibition on collagen-induced arthritis (CIA) and its impact on the plasma eicosanoid profile. We measured the eicosanoid metabolites by LC-MS/MS-based lipidomic analysis. The treatment with a sEH inhibitor significantly modulated 11 out of 69 eicosanoids, including increased epoxides 12(13)-EpODE, 12(13)-EpOME, 13-oxo-ODE, 15-HEPE, 20-COOH-LTB4 and decreases several diols 15,6-DiHODE, 12,13-DiHOME, 14,15-DiHETrE, 5,6-DiHETrE and 16,17-DiHDPE. Overall the inhibition of sEH in the rheumatoid arthritis model enhanced epoxides generally considered anti-inflammatory or resolutive mediators and decreased several diols with inflammatory features. These findings support the hypothesis that inhibiting the sEH increases systemic EpFA levels, advancing the understanding of the impact of these lipid mediators as therapeutical targets.
Chronic subdural hematoma (cSDH) is an increasingly prevalent condition, particularly among elderly population and is associated with elevated morbidity. The pathophysiology of cSDH involves proliferation of dural edge cells, fibroblasts, and release of vascular angiogenic factors leading to angiogenesis of a vascularized neomembrane perfused by the middle meningeal artery (MMA). MMA embolization is a technique that can be employed as treatment in conjunction with surgery or as a standalone therapy. Our aim is to describe our experience with treating selective cSDH patients with embolization of MMA in a university hospital in Argentina. We deployed this procedure in 6 patients over a period of one year and a half years with a median age of 72.5, with a median SDH thickness of 12.5 mm and four of them had a midline deviation greater than 5mm. The decision of the embolization was done due to minor symptoms and the necessity of restart antiplatelet therapy or anticoagulation, formal contraindication for surgery or as adjuvant of surgery because of cSDH recurrence. After discharge, no patient required a new surgical intervention. MMA embolization is impressive to be a safe and an option to treat cSDH. We present our experience in six patients in a hospital in Argentina.
Publications studying pharmacokinetics of oral administration of (-)-ephedrine support that (-)-ephedrine is metabolized into norephedrine. However, the metabolism pathway is unknown. Both the parent drug and the metabolite are excreted in urine. Limited data after IV administration of ephedrine support similar observations of urinary excretion of drug and metabolite. The plasma elimination half-life of ephedrine following oral administration was about 6 hours.

Ephedrine crosses the placental barrier [see Use in Specific Populations (8.1)].
Sevoflurane Group called group A patients will receive sevoflurane. The patients of group A will receive facial mask properly attached to your face, inspiratory fraction of sevoflurane 3%, with therapeutic target of 1.2% expired fraction into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. This procedure is sufficient to induce the pre anesthetic conditioning in the group exposed to sevoflurane. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.
Secreted phospholipase 2 (sPLA2) is the largest family of phospholipase A2 (PLA2) enzymes with 11 mammalian isoforms. Each sPLA2 exhibits different localizations and specific properties, being involved in a very wide spectrum of biological processes. The enzymatic activity of sPLA2 has been well described; however, recent findings have shown that they could regulate different signaling pathways by acting directly as ligands. Arachidonic acid (AA) and its derivatives are produced by sPLA2 in collaboration with other molecules in the extracellular space, making important impacts on the cellular environment, being especially relevant in the contexts of immunity and cancer. For these reasons, this review focuses on sPLA2 functions in processes such as the promotion of EMT, angiogenesis, and immunomodulation in the context of tumor initiation and progression. Finally, we will also describe how this knowledge has been applied in the search for new sPLA2 inhibitory compounds that can be used for cancer treatment.
FIELD: medicine, homeopathy, traditional therapy. SUBSTANCE: medicinal preparation contains curative substance in therapeutic dosage as material carrier. The latter is supplied with an information on biologically active substance prepared according to homeopathic technique. Biologically active substance in the form of antilogarithmic homeopathic preparation has an initial chemical formula similar to curative substance. New curative substances are characterized by enhanced biophysical properties and possess higher therapeutic efficiency. EFFECT: higher efficiency in combining homeopathic and traditional therapies.
Subjects were given license to use Beating the Blues, a commercially available iCBT program. Subjects were given 3 months to use the program.
Patients receive Lumason IV and undergo CEUS imaging with MRI/CT on study. Patients' electronic medical record is reviewed every 6 months throughout study.
Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 400mg BID( twice daily) for 28 days.
<P>PROBLEM TO BE SOLVED: To provide a medical imaging system having a function supporting a user for processing medical image data.  <P>SOLUTION: This method 130 is provided for automatically displaying information during processing medical images. This method 130 includes a process 134 for determining an image view to a display image 126 created from collected scanning data, and a process 136 for determining a text 124 for displaying it associated with a marker 122 to be displayed on the display image 126 based on the determined image view. The text 124 indicates a region specified by the marker 122 in the display image. This method further includes a process 138 for automatically displaying the text 124 determined associated with the marker 122 on the display image 126.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Insufficient Milk Perception Scale, Personal Information Form, Tendency to Discontinue Breastfeeding Scale and Breastfeeding Self-Efficacy Scale were also administered to the mothers. After discharge, training videos and written documents were sent to the mothers individually via telehealth application once a week. Visualised messages explaining breastfeeding and that breastmilk is sufficient for the baby were also sent via telehealth application five days a week. Mothers were video-called between 10.00-17.00 on weekdays and live support was provided by the investigators. Mothers in the intervention group were called via telehealth application between the 2nd-5th days, 13th-17th days, 38th-40th days, 2nd-3rd months, 4th-5th months and at the end of the 6th month postpartum and the relevant forms were applied again. In addition, the qualitative questions in the "Semi-structured Interview Form" were asked at the end of the 6th month.